MichaelKittMD

Internal Medicine • Mountain View, CA

Healthcare Research and Healthcare Policy

Physician

Join to view full profile

Dr. Kitt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kitt's full profile

Already have an account?

Office
3372 Shady Spring Ln
Mountain View, CA 94040
Phone+1 650-438-3676

Education & Training

Albany Medical CenterResidency, Internal Medicine, 1978 - 1981
New York University School of MedicineClass of 1978

Certifications & Licensure

MI State Medical License 1986 - 2026
NY State Medical License 1979 - 2026
CA State Medical License 1997 - 2025
PA State Medical License 1992 - 2004
American Board of Internal Medicine Internal Medicine

Clinical Trials

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia Start of enrollment: 2003 Aug 01
Completed
Phase 2
Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA) Start of enrollment: 2009 Mar 01
Completed
Phase 2
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) Start of enrollment: 2012 Mar 01
Completed
Phase 3
A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010) Start of enrollment: 2015 Mar 09
Completed
Phase 2
A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016) Start of enrollment: 2015 Aug 26
Completed
Phase 2
Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough Start of enrollment: 2017 Oct 03
Completed
Phase 2
A Dose Escalation Study of Bradanicline in Refractory Chronic Cough Start of enrollment: 2018 Nov 05
Completed
Phase 2
A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2015 Jul 20
Completed
Phase 2
Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014) Start of enrollment: 2015 Oct 28
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy Adults.
Jesse C Nussbaum, Azher Hussain, Peter Butera, Anthony P Ford, Michael M Kitt
Journal of Clinical Pharmacology. 2024-08-01
4 citations
Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled T...
Jaclyn A Smith, Michael M Kitt, Alan Bell, Nicolas Noulin, Anjela Tzontcheva
Pulmonary Therapy. 2022-09-01
44 citations
Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa.
Deborah M. Siegal, Genmin Lu, Janet M. Leeds, Mark Karbarz, Janice Castillo
Blood Advances. 2017-09-26